COVID Risk | Literature database and meta-analysis page 10

Last update : 2021-08-05 08:37:15 (GMT+2) | 276 factors investigated | 1766 estimates included | 219 articles processed | QC progress: 50%

Receive updates on COVID-19 risk factors

Associated factors

Risk category:

Risk name:

Outcomes

Outcome description:

Filters

Adjusted analysis:

Author:

Reset
Run a meta-analysis by selecting an Outcome & a Risk category or a Risk name & a Risk category, and click on the Submit button.

Green: significant protective factor
Red: significant risk factor
^§ adjusted estimate (see article details)
^† estimated using data reported in the article

Outcome	Risk category	Risk [exposed vs. unexposed]	Risk estimate (95% CI)	Author [URL]	View	QC
COVID-19 (severe/critical)	Findings	Radiological finding on admission [-400 ~ -200 Hounsfield unit (%) vs. Normal]	Odds ratio: 1.010 (0.990-1.041) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [> -200 Hounsfield units (%) vs. Normal]	Odds ratio: 0.990 (0.970-1.010) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of consolidation percentage in right lower lobe vs. Not applicable]	Odds ratio: 1.050 (0.970-1.150) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of consolidation percentage in right middle lobe vs. Not applicable]	Odds ratio: 1.060 (1.000-1.130) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of consolidation percentage in right upper lobe vs. Not applicable]	Odds ratio: 1.130 (1.030-1.250) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of consolidation percentage in left lower lobe vs. Not applicable]	Odds ratio: 1.060 (0.990-1.130) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of consolidation percentage in left upper lobe vs. Not applicable]	Odds ratio: 1.150 (1.010-1.320) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase in ground-glass opacity percentage in left lower lobe vs. Not applicable]	Odds ratio: 1.100 (0.990-1.230) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase in ground-glass opacity percentage in right middle lobe vs. Not applicable]	Odds ratio: 0.990 (0.850-1.140) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase in ground-glass opacity percentage in right upper lobe vs. Not applicable]	Odds ratio: 1.000 (0.820-1.220) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase in ground-glass opacity percentage in left lower lobe vs. Not applicable]	Odds ratio: 1.100 (0.990-1.230) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase in ground-glass opacity percentage in left upper lobe vs. Not applicable]	Odds ratio: 1.050 (0.920-1.210) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [1% increase of total lesion volume vs. Not applicable]	Odds ratio: 0.750 (0.500-1.130) ^§	Yu
COVID-19 (severe/critical)	Findings	Radiological finding on admission [Lung lobes involved vs. Normal]	Odds ratio: 1.500 (0.850-2.640) ^§	Yu
COVID-19 (severe/critical)	Patient characteristics	Age [1 year increase vs. Not applicable]	Odds ratio: 1.040 (1.010-1.060) ^§	Yu
COVID-19 (death)	Treatment	Concomitant medication [Treated with anticoagulats vs. Not received]	Hazard ratio: 0.790 (0.350-1.800)	Klok
COVID-19 (death)	Complications	Thrombotic complications [Present vs. Not present]	Hazard ratio: 5.400 (2.400-12.000)	Klok
COVID-19 (death)	Laboratory Findings	LDH [Abnormal vs. Normal]	Odds ratio: 1.010 (1.000-1.030) ^§	Benussi
COVID-19 (death)	Laboratory Findings	CRP [Abnormal vs. Normal]	Odds ratio: 1.000 (0.990-1.010) ^§	Benussi
COVID-19 (death)	Laboratory Findings	Platelet count [Abnormal vs. Normal]	Odds ratio: 0.980 (0.970-0.990) ^§	Benussi
COVID-19 (death)	Complications	Sequential Organ Failure Assessment (SOFA) score [1 unit increase vs. Not applicable]	Odds ratio: 4.470 (1.210-16.500) ^§	Benussi
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Odds ratio: 1.080 (0.990-1.180) ^§	Benussi
COVID-19 (severe/fatal)	Treatment	Treatment for COVID-19 [Treated with remdesivir vs. Not received]	Hazard ratio: 0.950 (0.550-1.640)	Wang
COVID-19 (clinical improvement)	Treatment	Treatment for COVID-19 [Treated with remdesivir vs. Not received]	Hazard ratio: 1.230 (0.870-1.750)	Wang
Prolonged duration of SARS-CoV-2 shedding	Status	Hospital lenght of stay [1 day increase vs. Not applicable]	Odds ratio: 1.604 (1.262-2.040) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Treatment	Treatment for COVID-19 [Treated with Immunoglobulin vs. Not received]	Odds ratio: 0.098 (0.009-1.102) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Treatment	Treatment for COVID-19 [Treated with Glucocorticoids vs. Not received]	Odds ratio: 3.965 (0.425-37.006) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Laboratory Findings	Serum ferritin [Abnormal vs. Normal]	Odds ratio: 0.969 (0.219-4.291) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Laboratory Findings	Lymphocyte count [Abnormal vs. Normal]	Odds ratio: 1.703 (0.328-8.836) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Laboratory Findings	Partial Pressure of Oxygen (PaO2) [1 unit increase vs. Not applicable]	Odds ratio: 0.990 (0.969-1.011) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Status	Time from symptom onset to admission [1 day increase vs. Not applicable]	Odds ratio: 1.740 (1.296-2.337) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Symptoms	Body temperature [Fever present vs. Not present]	Odds ratio: 5.200 (1.190-22.726) ^§	Qi
Prolonged duration of SARS-CoV-2 shedding	Symptoms	Sputum production [Present vs. Not present]	Odds ratio: 1.745 (0.448-6.793) ^§	Qi
COVID-19 (severe/fatal)	Treatment	Concomitant medication [Treated with biologics vs. Not received]	Odds ratio: 0.410 (0.030-6.590)	Damiani
COVID-19 (severe/critical)	Treatment	Concomitant medication [Treated with biologics vs. Not received]	Odds ratio: 3.410 (0.210-54.550)	Damiani
COVID-19 (any condition)	Treatment	Concomitant medication [Treated with biologics vs. Not received]	Odds ratio: 3.430 (2.250-5.730)	Damiani
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with corticosteroid vs. Not received]	Hazard ratio: 0.154 (0.033-0.724) ^§	Goicoechea
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.064 (0.996-1.138) ^§	Goicoechea
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with Lopinavir–Ritonavir vs. Not received]	Hazard ratio: 0.969 (0.107-8.741) ^§	Goicoechea
COVID-19 (death)	Treatment	Treatment for COVID-19 [Treated with Azithromycin vs. Not received]	Hazard ratio: 0.057 (0.005-0.697) ^§	Goicoechea
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.116 (1.008-1.236) ^§	Goicoechea
COVID-19 (death)	Laboratory Findings	LDH [1 unit increase vs. Not applicable]	Hazard ratio: 1.006 (1.001-1.011) ^§	Goicoechea
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.092 (0.984-1.212) ^§	Goicoechea
COVID-19 (death)	Laboratory Findings	Lymphocyte count [1 unit increase vs. Not applicable]	Hazard ratio: 0.996 (0.992-1.000) ^§	Goicoechea
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.058 (0.956-1.171) ^§	Goicoechea
COVID-19 (death)	Status	Time of hemodialysis [1 month increase vs. Not applicable]	Hazard ratio: 1.008 (1.001-1.015) ^§	Goicoechea
COVID-19 (death)	Patient characteristics	Age [1 year increase vs. Not applicable]	Hazard ratio: 1.070 (0.990-1.156) ^§	Goicoechea
COVID-19 (death)	Comorbidities	Chronic liver disease [Present vs. Not present]	Hazard ratio: 1.510 (1.210-1.880) ^§	Docherty
COVID-19 (death)	Comorbidities	Cancer [Present vs. Not present]	Hazard ratio: 1.130 (1.020-1.240) ^§	Docherty
COVID-19 (death)	Comorbidities	Dementia [Present vs. Not present]	Hazard ratio: 1.400 (1.280-1.520) ^§	Docherty

If a relevant publication escaped our attention, please contact us.